Hermitian analysis from Fourier series to Cauchy-Riemann geometry /

Por D'Angelo, John P.
Publicado em c201

Sharp local bounds for orders of contact

Por D'Angelo, John P.
Publicado em 1981

Sarcoma Immunotherapy: Past Approaches and Future Directions

Por D'Angelo, S. P., Tap, W. D., Schwartz, G. K., Carvajal, R. D.
Publicado em 2014

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”

Por D'Angelo, S. P., Tap, W. D., Schwartz, G. K., Carvajal, R. D.
Publicado no Sarcoma (2015)

Driver Mutations Determine Survival in Smokers and Never Smokers with Stage IIIB/IV Lung Adenocarcinomas

Por Paik, Paul K., Johnson, Melissa L., D’Angelo, Sandra P., Sima, Camelia S., Ang, Daphne, Dogan, Snjezana, Miller, Vincent A., Ladanyi, Marc, Kris, Mark G., Riely, Gregory J.
Publicado em 2012

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations

Por Janjigian, Yelena Y., Park, Bernard J., Zakowski, Maureen F., Ladanyi, Marc, Pao, William, D’Angelo, Sandra P., Kris, Mark G., Shen, Ronglai, Zheng, Junting, Azzoli, Christopher G.
Publicado em 2011

Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

Por D'Angelo, Sandra P., Pietanza, M. Catherine, Johnson, Melissa L., Riely, Gregory J., Miller, Vincent A., Sima, Camelia S., Zakowski, Maureen F., Rusch, Valerie W., Ladanyi, Marc, Kris, Mark G.
Publicado em 2011

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma(†)

Por Dickson, M. A., Mahoney, M. R., Tap, W. D., D'Angelo, S. P., Keohan, M. L., Van Tine, B. A., Agulnik, M., Horvath, L. E., Nair, J. S., Schwartz, G. K.
Publicado no Ann Oncol (2016)

Molecular Epidemiology of EGFR and KRAS Mutations in 3026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-related KRAS-mutant Cancers

Por Dogan, Snjezana, Shen, Ronglai, Ang, Daphne C, Johnson, Melissa L, D’Angelo, Sandra P, Paik, Paul K, Brzostowski, Edyta B, Riely, Gregory J, Kris, Mark G, Zakowski, Maureen F, Ladanyi, Marc
Publicado em 2012

High-risk features in radiation-associated breast angiosarcomas

Por D'Angelo, S P, Antonescu, C R, Kuk, D, Qin, L, Moraco, N, Carvajal, R C, Chi, P, Dickson, M A, Gounder, M, Keohan, M L, Singer, S, Schwartz, G K, Tap, W D
Publicado em 2013

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation

Por Kadota, Kyuichi, Yeh, Yi-Chen, D’Angelo, Sandra P., Moreira, Andre L., Kuk, Deborah, Sima, Camelia S., Riely, Gregory J., Arcila, Maria E., Kris, Mark G., Rusch, Valerie W., Adusumilli, Prasad S., Travis, William D.
Publicado no Am J Surg Pathol (2014)

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Por D’Angelo, Sandra P., Mahoney, Michelle R., Van Tine, Brian A., Adkins, Douglas R., Grosse Perdekamp, Maria T., Condy, Mercedes M., Luke, Jason J., Hartley, Eliza Woodward, Antonescu, Cristina R., Tap, William D., Schwartz, Gary K.
Publicado no Cancer Chemother Pharmacol (2015)

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma

Por Shoushtari, A. N., Landa, J., Kuk, D., Sanchez, A., Lala, B., Schmidt, N., Okoli, C., Chi, P., Dickson, M. A., Gounder, M. M., Keohan, M. L., Crago, A. M., Tap, W. D., D'Angelo, S. P.
Publicado no Sarcoma (2016)

Phase 2 Trial of the CDK4 inhibitor Palbociclib (PD0332991) at 125 mg dose in Well-Differentiated or Dedifferentiated Liposarcoma

Por Dickson, Mark A., Schwartz, Gary K., Keohan, Mary Louise, D’Angelo, Sandra P., Gounder, Mrinal M., Chi, Ping, Antonescu, Cristina R., Landa, Jonathan, Qin, Li-Xuan, Crago, Aimee M., Singer, Samuel, Koff, Andrew, Tap, William D.
Publicado no JAMA Oncol (2016)

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memor...

Por Horvat, Troy Z., Adel, Nelly G., Dang, Thu-Oanh, Momtaz, Parisa, Postow, Michael A., Callahan, Margaret K., Carvajal, Richard D., Dickson, Mark A., D'Angelo, Sandra P., Woo, Kaitlin M., Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Publicado no J Clin Oncol (2015)

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Por Dickson, Mark A., Tap, William D., Keohan, Mary Louise, D'Angelo, Sandra P., Gounder, Mrinal M., Antonescu, Cristina R., Landa, Jonathan, Qin, Li-Xuan, Rathbone, Dustin D., Condy, Mercedes M., Ustoyev, Yelena, Crago, Aimee M., Singer, Samuel, Schwartz, Gary K.
Publicado em 2013

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Por Dickson, Mark A., D'Adamo, David R., Keohan, Mary L., D'Angelo, Sandra P., Carvajal, Richard D., Gounder, Mrinal M., Maki, Robert G., Qin, Li-Xuan, Lefkowitz, Robert A., McKennon, Olivia R., Hirst, Catherine M., Schwartz, Gary K., Tap, William D.
Publicado no Sarcoma (2015)

Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas

Por Gounder, Mrinal, Desai, Ved, Kuk, Deborah, Agaram, Narasimhan, Arcila, Maria, Durham, Benjamin, Keohan, Mary L., Dickson, Mark A., D’Angelo, Sandra P., Shukla, Neerav, Moskowitz, Craig, Noy, Ariela, Maki, Robert G., Herrera, Diego Adrianzen, Sanchez, Armando, Krishnan, Anita, Pourmoussa, Andrew, Qin, Li-Xuan, Tap, William D.
Publicado no Eur J Cancer (2015)

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Por Naidoo, Jarushka, Schindler, Katja, Querfeld, Christiane, Busam, Klaus, Cunningham, Jane, Page, David B., Postow, Michael A., Weinstein, Alyona, Lucas, Anna Skripnik, Ciccolini, Kathryn T., Quigley, Elizabeth A., Lesokhin, Alexander M., Paik, Paul K., Chaft, Jamie E., Segal, Neil H., D‘Angelo, Sandra P., Dickson, Mark, Wolchok, Jedd D., Lacouture, Mario E.
Publicado no Cancer Immunol Res (2016)

Ipilimumab for Patients With Advanced Mucosal Melanoma

Por Postow, Michael A., Luke, Jason J., Bluth, Mark J., Ramaiya, Nikhil, Panageas, Katherine S., Lawrence, Donald P., Ibrahim, Nageatte, Flaherty, Keith T., Sullivan, Ryan J., Ott, Patrick A., Callahan, Margaret K., Harding, James J., D'Angelo, Sandra P., Dickson, Mark A., Schwartz, Gary K., Chapman, Paul B., Gnjatic, Sacha, Wolchok, Jedd D., Hodi, F. Stephen, Carvajal, Richard D.
Publicado em 2013